Occupational Therapists in Plainfield, IN Accepting Medicare

6 Occupational Therapists found. Showing 1 - 6

Krystal Walls, MSOTR Occupational Therapist - Physical Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5865 Sugar Ln, Plainfield, IN 46168 Phone: 317-839-7900

Ms. Jennifer Jo Brackney, MS OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5422 E County Road 600 S, Plainfield, IN 46168 Phone: 317-836-5484

Mrs. Dianne Elaine King, OTR Occupational Therapist - Gerontology Medicare: Not Enrolled in Medicare Practice Location: 8580 E County Road 300 S, Plainfield, IN 46168 Phone: 317-839-7435    Fax: 317-331-1074

Ms. Abigail Elaine Kamhi, MOT, OTR Occupational Therapist Medicare: Medicare Enrolled Practice Location: 5865 Sugar Ln, Plainfield, IN 46168 Phone: 317-680-7999

Mrs. Lesley Lynn Bray-lautenschlager, MS, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1550 Raymond St, Plainfield, IN 46168 Phone: 317-838-8916

Mrs. Heather Dawn Hart-elmore, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9209 Princeton Circle, Plainfield, IN 46168 Phone: 317-445-6637    Fax: 317-838-7793

News Archive

Trius Therapeutics' Phase 1 trial establishes safety and tolerability of IV torezolid phosphate for MRSA

Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).

Merck expects 2011 non-GAAP EPS to be in the range of $3.64 to $3.76

Following the Merck and Johnson & Johnson settlement announcement today, Merck said that it continues to expect 2011 non-GAAP earnings per share to be in the range of $3.64 to $3.76, excluding certain items.

New 3D scaffolding technology may help grow skin and blood vessels in labs

Scientists are developing new scaffolding technology which could be used to grow tissues such as skin, nerves and cartilage using 3D spaghetti-like structures. Their research is highlighted in the latest issue of Business, the quarterly highlights magazine of the Biotechnology and Biological Sciences Research Council (BBSRC).

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

Read more Medical News

› Verified 3 days ago